uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the likelihood of FDA approval for its leading drug candidate, AMT-130, during the period from September 24, 2025, to October 31, 2025 [2][3]. Group 1: Allegations and Impact - Robbins LLP is investigating allegations that uniQure misled investors about the FDA approval likelihood of AMT-130, claiming that the design of the pivotal study was not fully approved by the FDA and that the company downplayed the need for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies were adequate for a Biologics License Application (BLA) submission, leading to a significant stock price drop of $33.40 per share, or over 49%, from $67.69 to $34.29 [3]. Group 2: Shareholder Actions - Shareholders may be eligible to participate in the class action and must submit their papers to the court by April 13, 2026, if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].